Company news

Cnbx Pharmaceuticals Inc. (OTC:CNBX) news

Cnbx Pharmaceuticals Inc. news releases on 6ix. Latest, Nov 8, 2022: CNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest…

Cnbx Pharmaceuticals Inc. (OTC:CNBX) news

Press releases & updates

CNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharma

CNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer Therapy

CNBX Patent Application "Composition and Method for Treating Cancer with Cannabinoids" Enters National Phase in US and Israel

CNBX Peer-reviewed Study: "Possible Future Therapeutic Value" for CNBX Proprietary Drug Candidate

CNBX Pharmaceuticals Announces New Patent Granted in Australia

CNBX Pharmaceuticals Release a New Corporate Presentation

CNBX Pharmaceuticals Granted Patent in Hong Kong

Cannabics Pharmaceuticals Changes Name to CNBX Pharmaceuticals

CNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I/II (a) Clinical Trials

Meet CNBX at Radiation Therapy Conference (RTC) 2021 in Chicago

Radiation Oncology Expert Joins Cannabics Pharmaceuticals' Board of Advisors

EDISON Publishes Healthcare QuickView on Cannabics Pharmaceuticals: CNBX

CNBX Director, Dr. Inbar Maymon-Pomeranchik, to Participate at MJBizCon in Las Vegas

CEO of Cannabics Pharmaceuticals, Eyal Barad, to present at Edison Open Forum: Cannabinoids 2021

Cannabics Pharmaceuticals Files 2 Provisional Patents On Compositions and Methods for Treating Cancer

CEO Eyal Barad and Dr. David Sans from Cannabics Pharmaceuticals in NYC, to Participate at Benzinga's Cannabis Capital Conference

Cannabics Announces New Corporate Logo, New Website and New Company Presentation

Gabriel Yariv, Executive Director of Cannabics Pharmaceuticals and Dr. David Sans will participate at the ICDP Summit in Boston

Cannabics Pharmaceuticals hires Healthcare Investment Banker Dr. David Sans in New York to expand CNBX in Mental Health Diseases

Neuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired Medicine

Hemato-Oncology Expert, Dr. Sigal Tavor (MD) Joins Cannabics Pharmaceuticals' Board of Advisors

World-Renowned Melanoma Expert Joins Cannabics Pharmaceuticals' Board of Advisors

Cannabics Pharmaceuticals Appoints a Second Independent Board Member

Cannabics Pharmaceuticals Announces Appointment of New Independent Board Member

Cannabics Pharmaceuticals' Drug Candidate Exhibits 30% Tumor Volume Reduction in Mice

Cannabics Pharmaceuticals to launch Drug Development Programs for Prostate Cancer and Neurodegenerative & Mental Health Diseases

Cannabics Pharmaceuticals Launches a Breast Cancer Treatment Research Program

The European Patent Office Grants Cannabics Pharmaceuticals Patent for Company's Personalized Medicine Drug Discovery Technology

Cannabics Pharmaceuticals Files a PCT Patent Application for Proprietary Cancer Treatment Formulations

Cannabics Pharmaceuticals Receives Patent "Notice of Allowance" From The Mexican Patent and Trademark Office (IMPI)

Cannabics Pharmaceuticals Launches a New Research Program to develop a Melanoma Treatment Drug Candidate for FDA Approval Track

Cannabics Pharmaceuticals Launches Psilocybin and Psilocin Research Program

Cannabics Pharmaceuticals to Initiate in-vivo Dose Response Study on Proprietary Colorectal Cancer Drug Candidate RCC-33

Cannabics Pharmaceuticals' Drug Candidate RCC-33 Prolongs Survival Rate in Mice Inoculated with Human Colorectal Cancer Cells

Cannabics Pharmaceuticals' in-vivo Tumor Inhibitory Effect Study Concludes with a Statistical Significance of p ≤ 0.016

Cannabics Pharmaceuticals' in-vivo Study concludes with a 33% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer

Cannabics Pharmaceutical's Interim in-vivo Study Results Show a 27% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer

Cannabics Pharmaceuticals Initiates In-Vivo Animal Studies for FDA Pre-IND Meeting Package

Cannabics Pharmaceuticals Founds Digestix Bioscience Inc., a Subsidiary for Treatment of Precancerous and Early Stage Neoplastic Local Tumors

Cannabics Concludes a Pre-Clinical Study on Human Biopsies in Preparation for FDA pre-IND Meeting Request on Colorectal Cancer Drug Candidate RCC-33

Cannabics Pharmaceuticals receives "Intention to Grant a European Patent" notice for its System and Method for High Throughput Screening of Cancer Cells patent application

Cannabics Pharmaceuticals Prepares to Submit the FDA with a pre-IND Meeting Request for its Proprietary Colon Cancer Drug Candidate, CANNABICS™ RCC-33

Cannabics Pharmaceuticals to Establish a Division for its Antitumor Drug Candidate RCC-33

Cannabics Pharmaceuticals Appoints Dr. Dana Ben-Ami Shor (MD), Gastroenterologist, to its Scientific Board of Advisors

Cannabics Pharmaceuticals Initiates Penetration for Its Cannabinoid Diagnostic Platform Into European Markets

Cannabics Pharmaceuticals Appoints Dr. Erez Scapa, MD to its Scientific Board of Advisors

Cannabics Pharmaceuticals and Cannomed Collaborate to Develop Cannabis Strains Targeting Cancers

Cannabics Pharmaceuticals to Capitalize on Israel's Final Approval for the Export of Medical Cannabis

Cannabics Pharmaceuticals Files Provisional Patent on Composition and Method for Treating Colon Cancer With Cannabinoids

Cannabics Pharmaceuticals Appoints Prof. Zamir Halpern to Its Scientific Board of Advisors